Slide 1: FY2017 Results Presentation
For personal use only Elixinol Global Limited FY2017 Results Presentation DRAFT For the year ending 31 December 2017 27 February 2018
Slide 2: Disclaimer
Disclaimer This presentation contains summary information about Elixinol Group Limited (Elixinol) and its subsidiaries and their activities. The information in this For personal use only presentation does not purport to be complete. It should be read in conjunction with Elixinol’s other periodic and
Slide 3: About Us
About Us Our vision is to be a leading global supplier of premium hemp and medical cannabis products For personal use only ▪ Elixinol Global Limited (Elixinol) listed on ASX in January 2018 ▪ Elixinol operates across three distinct segments within the industrial hemp and medicinal cannabis sectors:
Slide 4: Strategically positioned for success
Strategically positioned for success Elixinol USA ▪ Generating strong revenues For personal use only The global nutraceutical ▪ Leading brand in the CBD nutraceutical market industry already exceeds ▪ Expanding retail and wholesale sales across the USA US$200bn in sales. Hemp ▪ Distribution in over
Slide 5: Company Highlights
For personal use only Company Highlights DRAFT
Slide 6: Company Financial Overview and Achievements
Company Financial Overview and Achievements FY2017 results are shown on a pro forma basis For personal use only ▪ Successful ASX listing in January 2018 IPO ▪ Oversubscribed Initial Public Offering (IPO) raising $20m ▪ Revenue of $16.5m up 62% vs FY2016 ▪ Gross profit improved to 64% exceeding prosp
Slide 7: Industry Overview
For personal use only Industry Overview DRAFT
Slide 8: Elixinol Global Segment Channels
Elixinol Global Segment Channels The Elixinol Group For personal use only operates in three distinct segments Cultivated from Cannabis Sativa L. within the Industrial Hemp Marijuana industrial hemp and medicinal Nutraceuticals Hemp Foods Medicinal Cannabis cannabis sectors ▪ Nutraceuticals are botan
Slide 9: USA Industrial Hemp
USA Industrial Hemp Industrial hemp is a sustainable and versatile crop with sales of approximately US$688m in the US in 2016 For personal use only Large addressable market… …with growing popularity as a medical treatment Elixinol USA manufactures and distributes hemp-derived Growth of the hemp-deri
Slide 10: Hemp-Derived Food
Hemp-Derived Food Hemp is emerging as a “super food” with a global market estimated to be US$544m in 2020 For personal use only Global growth driven by European & NA consumption Emergence of APAC as the lucrative market ▪ North America (NA) and Europe currently make up a large ▪ Asia Pacific (APAC)
Slide 11: Medicinal Cannabis
Medicinal Cannabis Emerging and nascent industry in Australia with growing public support For personal use only Supportive and secure legislative environment Potential size of opportunity ▪ The legislative framework suggests that Australia is taking a ▪ Medicinal cannabis is a nascent industry in Au
Slide 12: Business Overview
For personal use only Business Overview Company Presentation February 2018
Slide 13: Elixinol USA
Elixinol USA Vertically integrated distributor of CBD hemp-derived nutraceutical products For personal use only Elixinol US overview and it’s key value drivers Brand reputation Highest quality raw Best in class Global presence Progressing towards The Elixinol brand is materials products ▪ Worldwide
Slide 14: Hemp Foods Australia
Hemp Foods Australia Leading supplier of hemp-derived food products For personal use only Overview of HFA Growth opportunities ▪ Located in Northern Rivers, NSW ✓ Amended legislation to permit sale of hemp food products in Australia and NZ in November 2017 ▪ Since 2012, HFA has grown substantially,
Slide 15: Elixinol Australia
Elixinol Australia Elixinol is currently pursuing licences with the Office of Drug Control’s (ODC) Medicinal Cannabis Program whilst running a staged strategy to build a sustainable business model For personal use only Stage 1 Stage 2 Business model Education of “Authorised Research and Extraction a
Slide 16: Board & Management
For personal use only Board & Management DRAFT
Slide 17: Board and Management
Board and Management ▪ Founding Chairman, Cornerstone Health Andrew Duff For personal use only ▪ Previously CFO/Finance Director, Primary Health Care Ltd Non-Executive Chairman ▪ Unique operational experience of strategy execution in a growing scalable business ▪ Co-Founder of Elixinol USA, Elixinol
Slide 18: Financial Information
For personal use only Financial Information DRAFT
Slide 19: Income Statement
Income Statement For the year ending 31 December 2017 For personal use only Commentary on Pro forma results ▪ Revenue of $16.5m up 62% vs FY2016 exceeding prospectus forecast by 7% ▪ Gross profit improved to 64% exceeding prospectus forecast by 2% ▪ Elixinol USA EBITDA exceeding prospectus forecast
Slide 20: Financial Information: Balance Sheet
Financial Information As at 31 December 2017 Statutory (AU#039;000) Commentary For personal use only Current assets Cash and cash equivalents Trade and other receivables 18,834 1,211 ▪ $18.8m cash on hand to fund entry into Inventories 2,470 the Australian Medical Cannabis market Other 816 Total curren
Slide 21: Cash Flow
Cash Flow For period ending 31 Dec 2017 Commentary Pro forma For personal use only (A#039;000) Profit before tax (1,541) ▪ Positive pro forma Group EBITDA Depreciation 265 Acquisition amortisation Share of (loss)/profit of associates 1,296 44 ▪ Working capital growth mostly attributed to Changes in wor
Slide 22: Corporate Structure
For personal use only Corporate Structure DRAFT
Slide 23: Capital Structure
Capital Structure Elixinol has $18.8m cash on hand and is materially debt free at December 2017 For personal use only Capital Structure Feb-18 Key Statistics Fully Diluted Shares Outstanding (FDSO) 102,928,540 Last Close, 26 February 2018 1.48 Market Capitalisation ($’m) 152.3 Deduct Cash as at 31 D
Slide 24: Corporate Structure
Corporate Structure For personal use only Colorado, USA Bangalow, NSW Northern Rivers, NSW Core focus: cultivation and Core focus: cultivation and Core focus: cultivation and manufacture of hemp- manufacture of hemp- manufacture of CBD/THC derived CBD nutraceutical derived products for health medici
Slide 25: Appendix
For personal use only Appendix Company Presentation February 2018
Slide 26: Income Statement - Statutory
Income Statement - Statutory Income Statement Commentary For personal use only (AU#039;000) Statutory ▪ Entities were acquired 27 December 2017 Revenue - Cost of goods sold - ▪ Includes trading activities for only a 4 day Gross Profit - period when operations were closed GP% - Other income - ▪ Includes